TIAA CREF Investment Management’s Gyre Therapeutics GYRE Stock Holding History

TIAA CREF Investment Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$199K	Buy	3,278 +1,061	+48%	+$68.2K	﹤0.01%	2883
2018 Q4	$131K	Sell	2,217 -81	-4%	-$5.97K	﹤0.01%	2936
2018 Q3	$186K	Sell	2,298 -132	-5%	-$10.5K	﹤0.01%	2996
2018 Q2	$213K	Buy	+2,430	New	+$426K	﹤0.01%	3024
2014 Q2	–	Sell	-166	Closed	-$621K	–	3138
2014 Q1	$621K	Hold	166	–	–	﹤0.01%	2874
2013 Q4	$543K	Hold	166	–	–	﹤0.01%	2938
2013 Q3	$694K	Sell	166 -3	-2%	-$12.1K	﹤0.01%	2828
2013 Q2	$567K	Buy	+169	New	+$643K	﹤0.01%	2891

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TIAA CREF Investment Management's GYRE Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Gyre Therapeutics (GYRE) stake by 48% in Q1 2019, buying an estimated $68.2K and bringing the position to 3,278 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

TIAA CREF Investment Management first reported a position in GYRE in Q2 2013 and has held it in 8 quarters since. The position peaked at $694K in Q3 2013. 63 funds tracked by Wall St. Rank hold GYRE as of Q1 2019.

TIAA CREF Investment Management held 3,278 shares of Gyre Therapeutics worth $199K as of Q1 2019.
TIAA CREF Investment Management bought 1,061 Gyre Therapeutics shares in Q1 2019, an estimated $68.2K.
Gyre Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2883 holding.
TIAA CREF Investment Management first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 8 quarters since.
TIAA CREF Investment Management's Gyre Therapeutics position peaked at $694K in Q3 2013.
63 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.